FDA warns RonanRx over compounded GLP-1 marketing claims

The U.S. Food and Drug Administration sent a warning letter dated October 30, 2026 to RonanRx, Inc. dba RonanRx of Elgin, Texas, over claims about compounded semaglutide and tirzepatide on its website and its X account. The letter, MARCS-CMS 737905, was issued by FDA’s Center for Drug Evaluation and Research (CDER) and signed by Clint L. Narver, director of the Office of Compounding Quality and Compliance.

FDA said it identified the violations during a September 2026 review of ronanrx.com and associated social media. The agency said the claims make the products misbranded under sections 502(a) and 502(bb) of the Federal Food, Drug, and Cosmetic Act, which cover false or misleading labeling and, for compounded drugs, false or misleading advertising or promotion.

What FDA cited

Labels. Compounded tirzepatide products shown on the website and posted on X by @Ronan_Rx carried “RonanRx” on the pictured label. FDA said that suggests RonanRx is the compounder of the drugs “when in fact it is not.”

Website headings. The site grouped products under “Well-Studied Compounded Medications” and “FDA-Approved Compounded Medications.” The second heading was described as covering “Compounded medications whose active ingredient has at least one FDA-approved branded form for the indication described.” FDA wrote that “Compounded drug products are not FDA-approved,” and that disclaimers saying a preparation “may not itself be FDA-approved” did not undo the misleading overall impression.

X posts. FDA cited the account’s bio, “Explore GLP-1s like Ozempic,” and a pinned video that offered “drugs like Ozempic” for seventy-eight dollars a month and described the drugs, with an expletive bleeped, as legit.

‘American made.’ The same video called the products “American made” and “farm-to-table drugs,” and ended with confetti around an American flag. FDA said its records contain no drug listings for semaglutide or tirzepatide active pharmaceutical ingredients intended for compounding that identify a U.S.-registered establishment as the drug substance manufacturer. Based on those records, FDA said, the API was not made in the U.S., so the claims create “a misleading impression regarding the product’s true origin.”

What FDA asked for

FDA asked RonanRx to respond within 15 working days, including by identifying the entities that produce the compounded drugs on its website, providing a representative sample of labeling, and addressing or removing other misleading claims. The letter also advised the company to reassess advertising across all platforms, including television and social media.

A warning letter is FDA’s notice of concerns, not a court finding. It is not known whether RonanRx has responded or changed its marketing. For how these letters work and other GLP-1 and peptide letters FDA has issued, see FDA warning letters explained. FDA said in February it would act against mass-marketed compounded GLP-1s (report), and its September 2025 letters also cited misleading compounded-drug claims (report).

Separately, on November 4, 2026, BBB National Programs’ National Advertising Division recommended that telehealth company Good Life Meds drop health-benefit and “personalized” claims for its compounded tirzepatide product (report).

The full text is on FDA’s warning letter page.